Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06904482 · ClinicalTrials.gov registry record · Phase 2
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
A Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06904482 is a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 36 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06904482, a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Conditions Studied
Interventions
- BIOLOGICAL Haplo-Identical / Cord Blood Transplant
Study Locations (1)
Ohio
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2030-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06904482
The ClinicalTrials.gov registry entry for NCT06904482 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Haplo-Identical / Cord Blood Transplant is the first listed.
NCT06904482 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06904482 about?
NCT06904482 is a clinical study titled "Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood". The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
What is the current status of trial NCT06904482?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2025-08-13. Estimated completion is 2030-02-25.
What conditions does trial NCT06904482 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, aGVHD.
What interventions are being tested in trial NCT06904482?
The interventions under investigation include: Haplo-Identical / Cord Blood Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT06904482?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06904482 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.